Non-myeloablative stem-cell transplantation for immunotherapy of cancer and non-malignant diseases with allogeneic lymphocytes

Israel Medical Association Journal

Volumn 4, Issue 4, 2002, Pages 284-287

  Slavin, Shimon ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Allogeneic lymphocytes; Graft versus host disease; Stem cell transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; GANCICLOVIR;

ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BENIGN TUMOR; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CHEMOPROPHYLAXIS; DOSE RESPONSE; DRUG EFFICACY; EDITORIAL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE; MULTIPLE MYELOMA; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; RADIATION DOSE; STEM CELL TRANSPLANTATION; WHOLE BODY RADIATION; GENETIC DISORDER; HUMAN; IMMUNOLOGY; LEUKEMIA; NEOPLASM; NOTE;

GENETIC DISEASES, INBORN; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; LYMPHOCYTES; NEOPLASMS;

EID: 0036017365     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (33)

1. Engraftment and induction of GVL with fludarabine based non-ablative preparative regimens in patients with chronic lymphocytic leukemia and lymphoma
2. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
3. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases
4. Non-myeloablative stem cell transplantation and donor lymphocyte infusion for the treatment of cancer and life-threatening non-malignant disorders
5. Immunotherapy of cancer with alloreactive lymphocytes
6. Developments in hematopoietic stem-cell transplantation in the treatment of autoimmune diseases
7. Non-myeloablative stem-cell transplantation in the treatment of malignant and non-malignant disorders
8. Long-term survival of skin allografts in mice treated with fractionated total lymphoid irradiation
9. Transplantation of allogeneic bone marrow without graft vs host disease using total lymphoid irradiation
10. Correction of enzyme deficiency in mice by allogeneic bone marrow transplantation with total lymphoid irradiation
11. Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI)
12. Anti-tumor effects of allogeneic bone marrow transplantation in (NZB × NZW)F1 hybrids with spontaneous lymphosarcoma
13. Total lymphoid irradiation
14. Cellular-mediated immunotherapy of leukemia in conjunction with autologous and allogeneic bone marrow transplantation in experimental animals and man
15. Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes
16. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post allogeneic bone marrow transplantation
17. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
18. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
19. Allogeneic cell therapy of severe beta thalassemia major by displacement of host stem cells in mixed chimera by donor blood lymphocytes
20. Allogeneic cell-mediated and cytokine-activated immunotherapy for malignant lymphoma at the stage of minimal residual disease after autologous stem cell transplantation
21. Allogeneic cell mediated immunotherapy for breast cancer after autologous stem cell transplantation: A clinical pilot study
22. Antileukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation
23. Graft-versus-leukemia reactions after bone marrow transplantation
24. Outpatient PBSC allografts using immunosuppression with low-dose TBI before, and cyclosporine (CSP) and mycophenolate mofetil (MMF) after transplant
25. "Miniallografts": Ongoing trials in humans
26. A new non-myeloablative protocol using fludarabine and low-dose TBI in preparation for allogeneic blood stem cell transplantation for high risk patients with malignant and non-malignant disorders
27. Combining an allogeneic graft-vs-myeloma effect with high dose autologous stem cell rescue in the treatment of multiple myeloma
28. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation
29. Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens, in the treatment of a murine mammary carcinoma
30. Towards amplification of graft vs leukemia (GVL) effect while minimizing graft vs host disease (GVHD)
31. Immunotherapy of relapsed resistant chronic myelogenous leukemia post allogeneic bone marrow transplantation with alloantigens pulsed donor lymphocytes
32. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft versus leukemia